← Leaderboards
Bruce E. Markham
Phrixus Pharmaceuticals, Inc.
$2,385,027
Attributed
$2,385,027
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $622.9K · FY2007–12$1M$750K$500K$250K$0
'07
'08
'09
'10
'11
'12
Funding mix
By agency
NIH$2,385,027 · 6
By mechanism
R43$2,078,319 · 5
R41$306,708 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Prevent”
- Lawrence Corey · Fred Hutchinson Cancer Center$609,181,782
- Jeffrey P Krischer · University Of South Florida$605,511,231
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$530,065,238
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$499,311,118
- David Heimbrook · Leidos Biomedical Research, Inc.$496,394,926
Research focus
PreventHeart FailureMembranePoloxamer 188Pharmacologic SubstanceCardiacDystrophinMyocardiumAffectMedicalRepairedDoseHeartMuscle CellsCell MembraneBaseChronicCellsSealMouse ModelCalciumCanis FamiliarisMuscular DystrophiesIn Vivo
Grant awards (6)
Treatment of Muscular Dystrophy-associated Dilated Cardiomyopathy with P-188$622,877
R43 · FY2012 · HL · contact PI
Effects of P-188 on Respiratory Function and Diaphragm Degeneration in the mdx mo$583,225
R43 · FY2011 · NS · contact PI
Poloxamer 188 mechanism of action in ischemic heart failure.$306,708
R41 · FY2010 · HL · contact PI
Development of Poloxamer-188 for the Treatment of Muscular Dystrophy Associated H$379,487
R43 · FY2009 · HL · contact PI
Poloxamer-188 for the prevention of fibrosis during peritoneal dialysis$277,646
R43 · FY2008 · DK · contact PI
Chronic Treatment of Heart Failure With Poloxamer-188$215,084
R43 · FY2007 · HL · contact PI